



DANSKBIOTEK

Biotech Salon #24

June 8th, 2022, from 15:00-17:30

COBIS, M13, Ole Maaløes Vej 3, 2200 Copenhagen N

Biotech valuations as preparation for out-licensing and investment

What is your valuation based on? This dreaded question most CEOs, with pre-commercial drugs in their pipelines, hate to answer. Investors and Big Pharma executives of course know that any financial model will be inherently imprecise – yet they want you to present a valuation based on logical and data-driven assumptions.

This workshop, led by MSC Nordics, will go through the basics of why it makes sense to create a financial model for biotech companies to guide business planning, portfolio management and negotiation. We will use real world examples to illustrate best practice and common pitfalls we have experienced together with our life science clients.

Agenda:

- 14:30 Registration and networking
- 15:00 Welcome
- 15:05 Workshop on Biotech valuations as preparation for out-licensing and investment, led by:
 - Tobias Thornblad, Co-founder and Chairman - MSC Nordics
 - Julia Fransson, CEO - MSC Nordics
 - Stine Birk Hansen, Senior Management Consultant - MSC Nordics
- Key topics that will be covered include:
 - Valuation mechanics and how it relates to drug development
 - Why every biotech should create a valuation model
 - Common mistakes in valuations and how to avoid them
 - Gaining the upper hand in negotiations
- 16:30 Questions and discussions
- 17:00 Networking, snacks, and refreshments

Register here

The event is free of charge for members; however, non-members will be charged a fee of 500 DKK